The introduction of MUC16 promoter-driven gro-α shRNA vectors into ovarian cancer cells via nanoparticle complexes rich in follicle-stimulating hormone (FSH) peptides is a novel form of drug delivery that can deliver drugs more efficiently and can reduce the secretion of gro-α protein in ovarian cancer cells to inhibit tumor growth [78]. This evidence concerns the gene CXCL1 and ovarian carcinoma.